Visteon (VC) PT Raised to $135 at TD Cowen

TD Cowen analyst Itay Michaeli raised the price target on Visteon (NASDAQ: VC) to $135.00 (from $130.00) while maintaining a Buy rating.

The analyst commented: "Raising PT To $135 Post An Overall Solid CMD Albeit With Some Puts/Takes; Visteon's CMD delivered on most fronts with an above-consensus guide and a significant step-up in share buybacks (~28% of cap through '29). However, there were some drawbacks including rising memory costs & GM/F roll-offs. The stock pullback was understandable amid rising expectations, but leaves the shares attractively valued (5x EBITDA | 12x P/E) into an expected earnings inflection. PT to $135."

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Freedom Broker Starts Cerus (CERS) at Buy
• Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results